FDA Drug Regulations
FDA drug regulations govern the development, testing, approval, manufacturing, and marketing of pharmaceutical products. The process starts with preclinical research, moves through an Investigational New Drug (IND) application and clinical trials, and culminates in a New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) for generics.
Key Points
An IND application must be filed before beginning clinical trials in humans
Clinical trials proceed in three phases: Phase 1 (safety), Phase 2 (efficacy), Phase 3 (large-scale)
The NDA must contain full reports of safety and efficacy investigations
Generic drugs use the ANDA pathway, requiring bioequivalence but not new clinical trials
FDA can require postmarket studies and risk evaluation and mitigation strategies (REMS)
Key Areas
Investigational New Drugs
IND applications, clinical investigations, safety reports
New Drug Applications
NDA/ANDA process, labeling, supplements
Key Provisions
Clinical Trial Phases
Defines the three phases of clinical investigation. Understanding what each phase requires is essential for drug development planning.
NDA Content and Format
Specifies everything required in a New Drug Application, from chemistry and manufacturing to clinical data and labeling.